Clinical Trial Update: A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer [Phase 1]

View source ↗

Summary

This clinical trial update confirms that MEN2501 is being evaluated in a first-in-human Phase 1 study for platinum-resistant ovarian cancer, with recruitment cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• MEN2501

Snippet

Sponsor: Stemline Therapeutics, Inc. | Conditions: Platinum-resistant Ovarian Cancer | Phase 1 | Status: RECRUITING